- About us
- Join Putnam
A large oncology company was looking to capitalize on early advantages in the cell therapy market. The organization engaged Putnam to support the development of 10-year strategy, focused on continuous innovation across all aspects of the business – from discovering and in-licensing novel technologies, to clinical development optimization, manufacturing improvements, and supply chain enhancements.
Our team critically assessed the evolving market landscape, identifying key growth drivers, such as expanded indications with existing products and technologies, launches of new products with proven technologies and “bold bet” technologies, and projecting revenues. We also collaborated with the client to determine key pillars of successful strategy, grounded in detailed assessment of novel emerging technologies’ commercial potential.
We were able to deliver and reach consensus on a sound 10-year company strategy, starting with synthesizing team discussions into an executive summary for c-suite review with specific needs that would need to be addressed and associated budget requests. We put emphasis on a continuous innovation cycle informed by strategic focus, expansion, and smart bets.
Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients...
An emerging biotech sought Putnam’s guidance to design and execute the global commercialization of their asset for a rare oncology indication.
A global, top-10 pharma client sought Putnam’s guidance on developing a lean launch strategy for a novel cell therapy in oncology.